Strong Financial Performance and Growth Potential Drive Buy Rating for Adaptive Biotechnologies

William Blair analyst Andrew Brackmann has reiterated their bullish stance on ADPT stock, giving a Buy rating today.

Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Adaptive Biotechnologies’ strong financial performance and growth potential. The company reported a significant revenue beat in its MRD segment, surpassing consensus expectations by $8 million, and raised its full-year MRD revenue guidance by $10 million. This positive financial performance, coupled with the achievement of AEBITDA positivity ahead of schedule, indicates a solid path towards cash flow breakeven, reducing risk in the business model.
Moreover, several key drivers are expected to sustain this momentum. The clonoSEQ business is benefiting from increased clinical volumes, higher average selling prices, and expanded penetration into the community. Additionally, the company is seeing strong momentum in its pharmaceutical segment, with a substantial backlog of clinical trials. These factors, combined with anticipated new payer agreements, suggest further upside potential for the stock, supporting Brackmann’s Buy rating.

In another report released today, BTIG also maintained a Buy rating on the stock with a $14.00 price target.